当前位置: 首页 >> 检索结果
601. Growth rates and histopathological outcomes of small (6-9 mm) colorectal polyps based on CT colonography surveillance and endoscopic removal.
作者: B Dustin Pooler.;David H Kim.;Kristina A Matkowskyj.;Michael A Newton.;Richard B Halberg.;William M Grady.;Cesare Hassan.;Perry J Pickhardt.
来源: Gut. 2023年72卷12期2321-2328页
The natural history of small polyps is not well established and rests on limited evidence from barium enema studies decades ago. Patients with one or two small polyps (6-9 mm) at screening CT colonography (CTC) are offered CTC surveillance at 3 years but may elect immediate colonoscopy. This practice allows direct observation of the growth of subcentimetre polyps, with histopathological correlation in patients undergoing subsequent polypectomy.
603. B and T cell responses to the BNT162b2 COVID-19 mRNA vaccine are not impaired in germ-free or antibiotic-treated mice.
作者: Todd Norton.;Miriam Anne Lynn.;Charné Rossouw.;Arunasingam Abayasingam.;Griffith Perkins.;Pravin Hissaria.;Rowena Anne Bull.;David John Lynn.
来源: Gut. 2024年73卷7期1222-1224页 605. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis.
作者: Elina En Li Cho.;Chong Zhe Ang.;Jingxuan Quek.;Clarissa Elysia Fu.;Lincoln Kai En Lim.;Zane En Qi Heng.;Darren Jun Hao Tan.;Wen Hui Lim.;Jie Ning Yong.;Rebecca Zeng.;Douglas Chee.;Benjamin Nah.;Cosmas Rinaldi Adithya Lesmana.;Aung Hlaing Bwa.;Khin Maung Win.;Claire Faulkner.;Majd B Aboona.;Mei Chin Lim.;Nicholas Syn.;Anand V Kulkarni.;Hiroyuki Suzuki.;Hirokazu Takahashi.;Nobuharu Tamaki.;Karn Wijarnpreecha.;Daniel Q Huang.;Mark Muthiah.;Cheng Han Ng.;Rohit Loomba.
来源: Gut. 2023年72卷11期2138-2148页
Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease, with type 2 diabetes mellitus (T2DM) as a major predictor. Insulin resistance and chronic inflammation are key pathways in the pathogenesis of T2DM leading to NAFLD and vice versa, with the synergistic effect of NAFLD and T2DM increasing morbidity and mortality risks. This meta-analysis aims to quantify the prevalence of NAFLD and the prevalence of clinically significant and advanced fibrosis in people with T2DM.
606. Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8+ T cells.
作者: Xing Kang.;Changan Liu.;Yanqiang Ding.;Yunbi Ni.;Fenfen Ji.;Harry Cheuk Hay Lau.;Lanping Jiang.;Joseph Jy Sung.;Sunny H Wong.;Jun Yu.
来源: Gut. 2023年72卷11期2112-2122页
Roseburia intestinalis is a probiotic species that can suppress intestinal inflammation by producing metabolites. We aimed to study the role of R. intestinalis in colorectal tumourigenesis and immunotherapy.
607. Comparison of drugs for active eosinophilic oesophagitis: systematic review and network meta-analysis.
作者: Pierfrancesco Visaggi.;Brigida Barberio.;Giulio Del Corso.;Nicola de Bortoli.;Christopher J Black.;Alexander C Ford.;Edoardo Savarino.
来源: Gut. 2023年72卷11期2019-2030页
There is currently no recommendation regarding preferred drugs for active eosinophilic oesophagitis (EoE) because their relative efficacy is unclear. We conducted an up-to-date network meta-analysis to compare proton pump inhibitors, off-label and EoE-specific topical steroids, and biologics in EoE.
608. Temporal trend of mortality in patients with cirrhosis with primary biliary cholangitis and primary sclerosing cholangitis during the COVID-19 pandemic.
作者: Xinyuan He.;Ning Gao.;Fan Lv.;Fengping Wu.;Yi Liu.;Lamei Li.;Walid S Ayoub.;Yee Hui Yeo.;Fanpu Ji.
来源: Gut. 2024年73卷7期1217-1219页 609. Catecholamines and inflammation in advanced liver disease: more closely intertwined than expected?
作者: Hans Dieter Nischalke.;Christina Nischalke.;Franziska Schmalz.;Christine Möller.;Benjamin Krämer.;Alexandra Funken.;Adrian Goldspink.;Jacob Nattermann.;Christian Strassburg.;Philipp Lutz.
来源: Gut. 2024年73卷7期1219-1222页 610. Bismuth quadruple three-in-one single capsule three times a day increases effectiveness compared with the usual four times a day schedule: results from the European Registry on Helicobacter pylori Management (Hp-EuReg).
作者: Ángeles Pérez-Aisa.;Olga P Nyssen.;Alma Keco-Huerga.;Luís Rodrigo.;Alfredo J Lucendo.;Blas J Gomez-Rodriguez.;Juan Ortuño.;Mónica Perona.;José María Huguet.;Oscar Núñez.;Luis Fernandez-Salazar.;Jesus Barrio.;Angel Lanas.;Eduardo Iyo.;Pilar Mata Romero.;Miguel Fernández-Bermejo.;Barbara Gomez.;Ana Garre.;Judith Gomez-Camarero.;Luis Javier Lamuela.;Ana Campillo.;Luisa de la Peña-Negro.;Manuel Dominguez Cajal.;Luis Bujanda.;Diego Burgos-Santamaría.;Fernando Bermejo.;Víctor González-Carrera.;Ramón Pajares.;Pedro Almela Notari.;Javier Tejedor-Tejada.;Montserrat Planella.;Itxaso Jiménez.;Yolanda Arguedas Lázaro.;Antonio Cuadrado-Lavín.;Isabel Pérez-Martínez.;Edurne Amorena.;Jesús M Gonzalez-Santiago.;Teresa Angueira.;Virginia Flores.;Samuel J Martínez-Domínguez.;Manuel Pabón-Carrasco.;Benito Velayos.;Alicia Algaba.;Consuelo Ramírez.;Enrique Alfaro Almajano.;Manuel Castro-Fernandez.;Noelia Alcaide.;Patricia Sanz Segura.;Anna Cano-Català.;Natalia García-Morales.;Leticia Moreira.;Francis Mégraud.;Colm O'Morain.;Xavier Calvet.;Javier P Gisbert.
来源: Gut. 2023年72卷11期2031-2038页
The recommended schedule for single capsule bismuth quadruple therapy (scBQT, Pylera) includes a proton pump inhibitor (PPI) two times a day and three scBQT capsules four times a day. Four times a day treatments are inconvenient and reduce adherence. In contrast, adherence improves with three times a day schedules. In clinical practice, many gastroenterologists use four capsule scBQT three times a day. However, the effectiveness and safety of this latter approach remain uncertain.
611. An efficient strategy for evaluating new non-invasive screening tests for colorectal cancer: the guiding principles.
作者: Robert S Bresalier.;Carlo Senore.;Graeme P Young.;James Allison.;Robert Benamouzig.;Sally Benton.;Patrick M M Bossuyt.;Luis Caro.;Beatriz Carvalho.;Han-Mo Chiu.;Veerle M H Coupé.;Willemijn de Klaver.;Clasine Maria de Klerk.;Evelien Dekker.;Sunil Dolwani.;Callum G Fraser.;William Grady.;Lydia Guittet.;Samir Gupta.;Stephen P Halloran.;Ulrike Haug.;Geir Hoff.;Steven Itzkowitz.;Tim Kortlever.;Anastasios Koulaouzidis.;Uri Ladabaum.;Beatrice Lauby-Secretan.;Mārcis Leja.;Bernard Levin.;Theodore Robert Levin.;Finlay Macrae.;Gerrit A Meijer.;Joshua Melson.;Colm O'Morain.;Susan Parry.;Linda Rabeneck.;David F Ransohoff.;Roque Sáenz.;Hiroshi Saito.;Silvia Sanduleanu-Dascalescu.;Robert E Schoen.;Kevin Selby.;Harminder Singh.;Robert J C Steele.;Joseph J Y Sung.;Erin Leigh Symonds.;Sidney J Winawer.; .
来源: Gut. 2023年72卷10期1904-1918页
New screening tests for colorectal cancer (CRC) are rapidly emerging. Conducting trials with mortality reduction as the end point supporting their adoption is challenging. We re-examined the principles underlying evaluation of new non-invasive tests in view of technological developments and identification of new biomarkers.
612. Efficient plasma metabolic fingerprinting as a novel tool for diagnosis and prognosis of gastric cancer: a large-scale, multicentre study.
作者: Zhiyuan Xu.;Yida Huang.;Can Hu.;Lingbin Du.;Yi-An Du.;Yanqiang Zhang.;Jiangjiang Qin.;Wanshan Liu.;Ruimin Wang.;Shouzhi Yang.;Jiao Wu.;Jing Cao.;Juxiang Zhang.;Gui-Ping Chen.;Hang Lv.;Ping Zhao.;Weiyang He.;Xiaoliang Wang.;Min Xu.;Pingfang Wang.;Chuanshen Hong.;Li-Tao Yang.;Jingli Xu.;Jiahui Chen.;Qing Wei.;Ruolan Zhang.;Li Yuan.;Kun Qian.;Xiangdong Cheng.
来源: Gut. 2023年72卷11期2051-2067页
Metabolic biomarkers are expected to decode the phenotype of gastric cancer (GC) and lead to high-performance blood tests towards GC diagnosis and prognosis. We attempted to develop diagnostic and prognostic models for GC based on plasma metabolic information.
613. Mepolizumab for treatment of adolescents and adults with eosinophilic oesophagitis: a multicentre, randomised, double-blind, placebo-controlled clinical trial.
作者: Evan S Dellon.;Kathryn A Peterson.;Benjamin L Mitlyng.;Alina Iuga.;Christine E Bookhout.;Lindsay M Cortright.;Kacie B Walker.;Timothy S Gee.;Sarah J McGee.;Brenderia A Cameron.;Joseph A Galanko.;John T Woosley.;Swathi Eluri.;Susan E Moist.;Ikuo Hirano.
来源: Gut. 2023年72卷10期1828-1837页
We aimed to determine whether mepolizumab, an anti-IL-5 antibody, was more effective than placebo for improving dysphagia symptoms and decreasing oesophageal eosinophil counts in eosinophilic oesophagitis (EoE).
614. Treatment of adenoma recurrence after endoscopic mucosal resection.
作者: David J Tate.;Lobke Desomer.;Maria Eva Argenziano.;Neha Mahajan.;Mayenaaz Sidhu.;Sergei Vosko.;Neal Shahidi.;Eric Lee.;Stephen J Williams.;Nicholas G Burgess.;Michael J Bourke.
来源: Gut. 2023年72卷10期1875-1886页
Residual or recurrent adenoma (RRA) after endoscopic mucosal resection (EMR) of large non-pedunculated colorectal polyps (LNPCPs) of ≥20 mm is a major limitation. Data on outcomes of the endoscopic treatment of recurrence are scarce, and no evidence-based standard exists. We investigated the efficacy of endoscopic retreatment over time in a large prospective cohort.
616. Microbiome variance of the small bowel in Crohn's disease.
作者: Lucas Wauters.;Raul Y Tito.;Matthias Ceulemans.;An Outtier.;Leen Rymenans.;Chloë Verspecht.;João Sabino.;Marc Ferrante.;Séverine Vermeire.;Tim Vanuytsel.;Jeroen Raes.
来源: Gut. 2023年72卷8期1626-1628页 617. Multivalent tyrosine kinase inhibition promotes T cell recruitment to immune-desert gastric cancers by restricting epithelial-mesenchymal transition via tumour-intrinsic IFN-γ signalling.
作者: Long Long Cao.;Heng Lu.;Mohammed Soutto.;Nadeem Bhat.;Zheng Chen.;Dunfa Peng.;Ahmed Gomaa.;Jia Bin Wang.;Jian Wei Xie.;Ping Li.;Chao Hui Zheng.;Sachiyo Nomura.;Jashodeep Datta.;Nipun Merchant.;Zhi Bin Chen.;Alejandro Villarino.;Alexander Zaika.;Chang Ming Huang.;Wael El-Rifai.
来源: Gut. 2023年72卷11期2038-2050页
Gastric cancer (GC) ranks fifth in incidence and fourth for mortality worldwide. The response to immune checkpoint blockade (ICB) therapy in GC is heterogeneous due to tumour-intrinsic and acquired immunotherapy resistance. We developed an immunophenotype-based subtyping of human GC based on immune cells infiltration to develop a novel treatment option.
618. Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells.
作者: Alessia Potenza.;Chiara Balestrieri.;Martina Spiga.;Luca Albarello.;Federica Pedica.;Francesco Manfredi.;Beatrice Claudia Cianciotti.;Claudia De Lalla.;Oronza A Botrugno.;Cristina Faccani.;Lorena Stasi.;Elena Tassi.;Silvia Bonfiglio.;Giulia Maria Scotti.;Miriam Redegalli.;Donatella Biancolini.;Barbara Camisa.;Elena Tiziano.;Camilla Sirini.;Monica Casucci.;Chiara Iozzi.;Danilo Abbati.;Fabio Simeoni.;Dejan Lazarevic.;Ugo Elmore.;Guido Fiorentini.;Giulia Di Lullo.;Giulia Casorati.;Claudio Doglioni.;Giovanni Tonon.;Paolo Dellabona.;Riccardo Rosati.;Luca Aldrighetti.;Eliana Ruggiero.;Chiara Bonini.
来源: Gut. 2023年72卷10期1887-1903页
Colorectal tumours are often densely infiltrated by immune cells that have a role in surveillance and modulation of tumour progression but are burdened by immunosuppressive signals, which might vary from primary to metastatic stages. Here, we deployed a multidimensional approach to unravel the T-cell functional landscape in primary colorectal cancers (CRC) and liver metastases, and genome editing tools to develop CRC-specific engineered T cells.
619. Drug rediscovery in gastroenterology: from off-label to on-label use of thioguanine in inflammatory bowel disease.
作者: Nanne K H de Boer.;Melek Simsek.;Berrie Meijer.;Markus F Neurath.;Ad van Bodegraven.;Chris J J Mulder.
来源: Gut. 2023年72卷10期1985-1991页
Drug rediscovery refers to the principle of using 'old' drugs outside the indications mentioned in the summary of product characteristics. In the past decades, several drugs were rediscovered in a wide variety of medical fields. One of the most recent examples is the unconditional registration of thioguanine (TG), a thiopurine derivative, in patients with inflammatory bowel disease in the Netherlands. In this paper, we aim to visualise potential hurdles that hamper drug rediscovery in general, emphasise the global need for optimal use and development of potentially useful drugs, and provide an overview of the registration process for TG in the Netherlands. With this summary, we aim to guide drug rediscovery trajectories in the near future.
620. Clarithromycin-containing triple therapy for Helicobacter pylori eradication is inducing increased long-term resistant bacteria communities in the gut.
作者: Olga Sjomina.;Reinis Vangravs.;Elīna Ļeonova.;Inese Poļaka.;Dārta Pūpola.;Kristaps Čivkulis.;Aleksandra Jeniceka.;Sergejs Paršutins.;Ilmārs Stonāns.;Jin Young Park.;Lars Engstrand.;Mārcis Leja.
来源: Gut. 2024年73卷7期1214-1215页 |